and so forth, with potentially unfavorable effects on the hemodynamics.
Therefore, based on the perspective that it is important to place patients under cardiopulmonary bypass (CPB) in the early stage to reduce myocardial oxygen consumption, we performed CABG under CPB as a matter of policy for cases of ACS at our institution.
Additionally, it has been reported in recent years that over the long term, graft patency is less satisfactory after OPCAB as compared with that after conventional CABG; 7 we therefore believe that in cases with ACS, high-quality CABG is important to maintain good graft patency and prevent the occurrence of cardiac events over the long term.
Human atrial natriuretic peptide (hANP) is a biological hormone secreted in response to atrial stretch, and its beneficial effects include: (1) vasodilatory and strong diuretic effects; (2) suppression of secretion of hormones such as those of the renin-angiotensin-aldosterone (RAA) system and catecholamines; (3) prevention of worsening of the electrolyte imbalance caused by the administration of a large amount of diuretic drugs by virtue of its natriuretic action; (4) reduction of myocardial oxygen demand; and (5) a dilatory effect on the coronary arteries. [8] [9] [10] In recent cardiovascular literature, new effects, such as the protective effect on the myocardium and suppression of left ventricular (LV) remodeling have also been reported. [11] [12] [13] During cardiac surgery conducted under CPB, the CPB is associated with an abnormally excessive release of biological hormones such as those of the RAA system and Circ J 2007; 71: 1401 -1407 (Received March 19, 2007 ; revised manuscript received May 9, 2007;  accepted June 5, 2007) Departments of Cardiovascular Surgery, *Cardiology, Nihon University School of Medicine, Tokyo, Japan Mailing address: Akira Sezai, MD, Department of Cardiovascular Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan. E-mail: asezai@med. nihon-u.ac.jp
Efficacy of Continuous Low-Dose hANP Administration in Patients Undergoing Emergent Coronary Artery Bypass Grafting for Acute Coronary Syndrome
catecholamines, which cause problems such as an oliguria and water retention in the third space. Therefore, based on the speculation that administration of hANP might be effective for overcoming these problems associated with CPB, our institution adopted, for the first time in the world, the continuous low-dose administration of hANP from the start of CPB during cardiac surgery under CPB. As a result of adopting this practice, we have observed suppression of water retention in the third space, reduction in the peripheral vascular resistance, suppression of activation of the RAA system, and strong diuresis in these patients, suggesting that hANP is effective for overcoming some of the major drawbacks associated with CPB. 14, 15 In the present study, we investigated the effects of continuous low-dose administration of hANP during and after emergent CABG for ACS in attenuating ischemia-reperfusion injury and suppressing LV remodeling.
Methods
The subjects of the study were 124 patients who underwent emergent CABG for ACS at our institution. Emergency surgery was defined as being performed within 24 h after onset. Patients were considered eligible when ischemia or infarction was observed in the territory of the left anterior descending coronary artery (LAD) and there was no preoperative evidence of renal dysfunction. We randomly assigned the patients into 2 groups as follows: 1 group to receive a continuous administration of hANP (Suntory Ltd, Osaka, Japan, and Daiichi Pharmaceutical Co, Ltd, Tokyo, Japan) from the start of CPB (hANP group: 63 cases), and 1 group to not receive hANP (physiological saline alone; non-hANP group: 61 cases). Prior to the start of the study, we provided a detailed explanation of the study objective to the patients and/or to their families and obtained their informed consent. The study was performed with the approval of the Ethics Committee of Nihon University Itabashi Hospital. In the hANP group, the administration of hANP started at a dose of 0.02 g·dl -1 ·min -1 at the start of CPB; the dose was subsequently decreased to 0.01 g·dl -1 ·min -1 after the beginning of oral drug administration, and the drug was discontinued 12 h after the beginning of oral drug administration. In the non-hANP group, the physiological saline was administered in the same dosing pattern. CABG was performed using the CPB in all cases. St Thomas solution at 4°C was used as the cardioplegic solution; it was administered at the initial dose of 30 ml/kg, followed after 1 h by administration, as required, of 10 ml/kg at intervals of 30 min.
The following parameters were investigated in the 2 study groups: the operative outcome; late postoperative outcome until 2 years after the operation (survival and cardiac events); postoperative peak creatine kinase (CK)-MB, lactate, blood urea nitrogen (BUN), and creatinine (Cr); dose of furosemide; amount of KCL needed for correction of the serum potassium; incidence of arrhythmias; length of time on artificial respiration (duration of tracheal intubation) after return to the ICU; duration of the requirement for postoperative intraaortic balloon pump (IABP) support; postoperative blood level of brain natriuretic peptide (BNP); and LV ejection fraction (EF), LV end-diastolic pressure (LVEDP) and LV end-diastolic volume index (LVEDVI) determined by cardiac catheterization at 1 month after the operation. As a matter of policy, we do not perform left ventriculography at our institution for cases of ACS; for this reason, we were unable to assess the preoperative LV function by cardiac catheterization. Basically, in the CABG, the LITA was used for the LAD in all cases, and the radial artery or saphenous vein was used for other sites. In regard to the medication used after the operation, aspirin (81 mg/day), warfarin (controlled at an INR of 1.5-2.0), a nitroglycerin preparation (40 mg/day), and furosemide (20 mg/day) were administered orally in both groups from the point of time at which oral administration became possible. No angiotensinconverting enzyme-inhibitors (ACEI), -blockers or ARBs were administered to any of the patients in either group. Oral spironolactone (50 mg/day) was administered in all the AMI cases. In cases with a systolic blood pressure of 150 mmHg or higher, a Ca channel antagonist was administered orally for blood pressure control.
The measured values were expressed as mean ± standard deviation. For statistical evaluation, the unpaired t-test was used to compare the patient characteristics, postoperative peak CK-MB, lactate, BUN, and Cr, dose of furosemide, and the amount of KCL needed for correction of the serum potassium, the respiratory index, the duration of tracheal intubation, and the duration of support with IABP in the postoperative period; the chi-square test for independence was used for comparison of the patient characteristics and incidence of arrhythmias, and repeated-measures ANOVA was used for other items. Survival and the incidence of cardiac events until 2 years after the operation were analyzed by using the KaplanMeier method, and the statistical evaluation was conducted using the log-rank test. Differences were judged to be statistically significant at p values <0.05.
Results

Clinical Characteristics
In regard to the preoperative patient characteristics, there were no significant differences in terms of age, male/female ratio, risk factors, frequency of need for IABP, frequency of left main trunk lesions, peak CK-MB, or EF as determined by echocardiography between the 2 groups (Table 1) . In this study, we defined troponin I-positive patients, in whom the CK-MB level was increased 2-fold or more in comparison with the normal value, as having AMI. The other patients were regarded as having unstable angina pectoris (UA).
Postoperative Outcomes
The number of vessels requiring bypass, duration of aortic clamping, and the duration of CPB are shown in Table 2 ; there were no significant differences in any of these parameters between the hANP and non-hANP groups. Postoperative in-hospital death occurred in 4 cases (6.3%) in the hANP group and 5 cases (8.2%) in the non-hANP group; the difference in the mortality between the 2 groups was not statistically significant. Of the 9 cases of death, 8 had AMI (including 4 cases from the hANP group and 4 cases from the non-hANP group) and 1 case (from the non-hANP group) had UA. The causes of death in the 4 cases from the hNAP group were pneumonia (2 cases), low-output syndrome (LOS) (1 case), and arrhythmia (1 case), and in the 4 cases from the non-hNAP group, the causes of death included LOS (2 cases), cardiac failure (2 cases), and arrhythmia (1 case). Evaluation including all the study subjects revealed that the tracheal intubation time was significantly shorter in the hANP group as compared with that in the nonhANP group, however, when the UA and AMI cases were evaluated separately, no statistically significant difference was found between the 2 groups. The results of both allcase evaluation and independent UA-/AMI-case evaluation revealed that the postoperative duration of IABP support was significantly shorter in the hANP group as compared with that in the non-hANP group. In the AMI cases, there was no significant difference in the postoperative length of ICU stay between the 2 groups, however, the results of evaluation of all cases and the UA cases alone revealed a significantly shorter postoperative length of ICU stay in the hANP group as compared with that in the non-hANP group. The length of hospital stay after the operation was also significantly shorter in the hANP group as compared with that in the non-hANP group, regardless of the method of evaluation (all cases or independent UA-/AMI-case evaluation). Late postoperative death occurred in 2 cases in the hANP group (including 1 case of UA with cardiac failure and 1 case of UA with ovarian cancer; there were no late postoperative deaths among the AMI cases in this group) and 4 cases in the non-hANP group (including 2 cases of UA with cardiac failure and 1 case each of AMI with cardiac failure and arrhythmia). The cumulative survival rate as analyzed by the Kaplan -Meier method was 90.5% in the hANP group and 85.2% in the non-hANP group in the all-case evaluation; the difference was not statistically significant (p=0.368). When the UA/AMI cases were evaluated separately, the survival rate for the UA cases was 95.2% in the hANP group and 92.5% in the non-hANP group (p=0.591), and was 81.0% and 71.4% in the 2 groups, respectively (p=0.501) for the AMI cases; the differences between the hANP and non-hANP groups not being significant for either the UA or the AMI cases (Fig 1) . The survival rates taking into consideration only cardiacrelated causes of death were 92.0% in the hANP group and 85.2% in the non-hANP group in the all-case evaluation; the difference not being significant (p=0.236). The corresponding rates in the hANP and non-hANP groups were 97.6% and 92.5%, respectively, (p=0.282) in the UA-case evaluation, and 81.0% and 71.4%, respectively, (p=0.501) in the AMI-case evaluation; the differences not being significant in either case (Fig 2) . The distribution of cardiac events developing postoperatively in the 2 groups were as follows: in the hANP group, 14 cases developed arrhythmias (UA, 8 cases; AMI, 6 cases), 3 cases developed cardiac failure (UA, 2 cases; AMI, 1 case), and 1 case developed angina (UA, 1 case); in the non-hANP group, 26 cases developed arrhythmias (UA, 14 cases; AMI, 12 cases), 9 cases developed cardiac failure (UA, 5 cases; AMI, 4 cases), and 1 case developed angina (UA, 1 case). The rate of avoidance of cardiac events as analyzed by the Kaplan -Meier method was 84.0% in the hANP group and 41.0% in the non-hANP group in the allcase evaluation, which was significantly higher in the hANP group as compared with that in the non-hANP group (p<0.0001). When the UA/AMI cases were evaluated separately, the rate was 85.7% in the hANP group and 47.5% in the non-hANP group (p=0.0001) for the UA cases, and 81.0% and 28.6% in the 2 groups, respectively (p=0.0007) for the AMI cases; the rate being significantly higher in the hANP group for both UA and AMI cases (Fig 3) .
BNP (Table 4)
There was no difference in the preoperative blood level of BNP between the 2 groups, but for all cases, on the other hand, the value was significantly lower in the hANP group as compared with that in the non-hANP group on Day 0 (p=0.022), at 1 month (p=0.003), at 6 months (p=0.004), and at 1 year (p=0.002) after the operation. In the independent UA-/AMI-case evaluation, the value was lower in the hANP group than that in the non-hANP group on Day 0 (p=0.046), at 1 month (p=0.048), at 6 months (p=0.004) and at 1 year (p=0.002) after the operation in the UA cases, but there was no significant difference in the distant stage at 6 months and 1 year after the operation. In the AMI cases, there was no significant difference between the hANP and non-hANP groups in the acute stage, that is, on Day 0 and at 1 week after the operation, the value was significantly lower in the hANP group as compared with that in the nonhANP group in the intermediate and late postoperative phases, that is, at 1 month (p=0.02), at 6 months (p=0.002), and at 1 year (p=0.003) after the operation. (Table 5 ) As shown in Table 5 , in the all-case evaluation, the EF was significantly higher in the hANP group as compared with that in the non-hANP group, and the LVEDP and LVEDVI were significantly lower in the hANP group as compared with the values in the non-hANP group. When the UA cases were evaluated independently, no significant difference was seen between the 2 groups in terms of the EF, however, the LVEDP and LVEDVI were significantly lower in the hANP group as compared with the values in the non-hANP group. In the AMI cases, in contrast, the EF was significantly higher in the hANP group as compared with that in the non-hANP group, and the LVEDP and LVEDVI were significantly lower in the hANP group as compared with the values in the non-hANP group.
Cardiac Catheterization at 1 Month After the Operation
Incidence of Arrhythmia
The incidence rate of ventricular tachycardia after the operation was significantly lower in the hANP group as compared with that in the non-hANP group (p=0.027) in the all-case evaluation, however, no significant difference in the rate between the 2 groups was noted in the independent UA/AMI-case evaluations. The incidence rate of premature ventricular contractions was significantly lower in the hANP group as compared with that in the non-hANP group in both the all-case evaluation and the independent UA-/AMI-case evaluations. The incidence rate of atrial fibrillation was also significantly lower in the hANP group as compared with that in the non-hANP group in both the allcase evaluation and the independent UA-/AMI-case evaluations.
Blood Biochemistry Data
There was no significant difference in the postoperative peak CK-MB between the 2 groups when the UA cases were evaluated independently (p=0.090), however, the peak level was found to be significantly lower in the hANP group as compared with that in the non-hANP group in both the all-case and independent AMI-case evaluations (all cases: p=0.007; AMI cases: p=0.031). The postoperative peak lactate level was significantly lower in the hANP group as compared with that in the non-hANP group in the all-case as well as the independent UA-/AMI-case evaluations.
Renal Function
There was no significant difference in the postoperative peak BUN between the 2 groups when the AMI cases were evaluated independently (p=0.058), however, the peak level was significantly lower in the hANP group as compared with that in the non-hANP group according to the all-case and independent UA-case evaluations (all cases, p=0.002; UA cases, p=0.009). The postoperative peak Cr was significantly lower in the hANP group as compared with that in the non-hANP group in the all-case evaluations, as well as in the independent UA-/AMI-case evaluations. None of the cases in the hANP group required postoperative hemofiltration, while 2 cases in the non-hANP group (UA, 1 case; AMI, 1 case) required HF. In 1 of these 2 cases, the recovery of renal function occurred without the need for maintenance hemodialysis, however, the other case died of renal failure. The dose of furosemide was significantly lower in the hANP group as compared with that in the non-hANP group in the all-case, as well as the independent UA-/AMIcase evaluations. The dose of KCL required for serum potassium correction was also significantly lower in the hANP group as compared with that in the non-hANP group in the all-case, as well as the independent UA-/AMI-case evaluations.
Discussion
The preoperative condition, measures taken for myocardial protection, and postoperative management can be considered as the key factors influencing the patient prognosis after emergent CABG for ACS. Our institution was the first in the world to adopt the strategy of continuous low-dose administration of hANP from the start of CPB during cardiac surgery under CPB, and we have been using this strategy successfully for many years. 14, 15 As a result of adopting this strategy, we have observed a suppression of water retention in the third space, reduction of peripheral vascular resistance, suppression of activation of the RAS system, and strong diuresis in patients placed on the CPB, thereby demonstrating that hANP is effective for overcoming some of the major problems associated with CPB. In addition, because of the reduced dose of furosemide needed postoperatively and the smaller amount of potassium needed for correction of the potassium level, the worsening of electrolyte balance and occurrence of arrhythmias are avoided in the unstable stage after the operation; therefore, we believe that this is a promising drug in the drug armamentarium used for postoperative management in cases undergoing cardiac surgery. 14 effect on LV remodeling of palliative CABG from a randomized prospective study of 200 cases. 15 hANP is a peptide consisting of 28 amino acids that is secreted in response to stretching of the atrial walls. It has been demonstrated to have a variety of actions, including promotion of natriuresis, inducing vasodilatation, suppressing activation of the RAS system, and causing coronary arterial vasodilation. [8] [9] [10] Because of its various pharmacological actions, it has attracted attention as a novel therapeutic drug for cardiac failure. Furthermore, in recent years, hANP has been shown to be efficacious for attenuating ischemia-reperfusion injury and suppressing LV remodeling after AMI. Hayashi et al demonstrated that administration of hANP after PCI in AMI cases suppressed the release of aldosterone, angiotensin-II and endothelin-1, all of which promote myocardial fibrosis, thereby suppressing LV remodeling. 11 Kuga et al reported that administration of hANP suppressed ventricular arrhythmias and attenuated ischemia-reperfusion injury. 12 In an experiment using an animal model of ischemia-reperfusion injury, the administration of hANP was reported to prevent the high-energy phosphate level decline in the myocardium and to prevent reperfusion-induced arrhythmias. 16 In Japan, a large-scale study called the "J-WIND KATP study" was initiated to determine the effects of hNAP administration after PCI in AMI patients. 17 Although an article was not yet announced, the results of the study were presented at the 2006 Annual Meeting of the American Heart Association.
It was suggested at this forum, that because the incidence rate of permanent myocardial damage was reduced by 14.7% and the rate of re-hospitalization because of cardiac failure was reduced by 83.6% in the hANP group relative to the values in the control group, the treatment strategies for myocardial infarction in the acute stage might change. In the present investigation, there was no difference in the operative mortality rate between the hNAP and the nonhNAP groups, however, the postoperative peak CK-MB and lactate levels were significantly lower, the LVEDP and LVEDVI determined by cardiac catheterization at 1 month after the operation were significantly lower, and the postoperative blood BNP values were significantly lower in the hANP group as compared with the corresponding observations in the non-hANP group. Particularly in cases of AMI, these differences were observed until the late postoperative period. In addition, the rate of non-occurrence of cardiac events until 2 years after the operation was significantly higher in the hANP group as compared with that in the non-hANP group, and this strongly suggests that treatment with hANP can prevent the occurrence of postoperative arrhythmias and cardiac failure.
Based on the results of this study, we consider that the administration of hANP represents an effective adjuvant therapy for the prevention of LV remodeling as well. The importance of the role of neurohumoral factors, particularly that of the RAA system, in the process of LV remodeling has been pointed out. 18 We have shown in previous studies that administration of hANP during cardiac surgery suppresses activation of the RAA system, although this was not evaluated in the present study. We therefore consider that this effect might also be involved in the suppression of LV remodeling after the operation in patients receiving this drug. Aldosterone has been reported to facilitate the synthesis of cardiac collagen and proliferation of fibroblasts via mineralocorticoid receptors, 19 and hormones of the RAA system, in particular, aldosterone, have been reported to be strongly associated with LV remodeling. The present study showed that hANP attenuates ischemia-reperfusion injury and suppresses LV remodeling. These actions were particularly noticeable in the AMI cases. It has been reported that LV end-diastolic volume is an important factor determining the survival prognosis in the remote postoperative period, 20 and that cardiac enlargement caused by progressive LV remodeling influences the prognosis. 21 Therefore, suppression of LV remodeling is important in AMI patients. Before the start of this study, no study had investigated the efficacy of ACEI, ARB, or -blockers on the RAA system or the longterm effects on ischemic heart disease. However, recently, various studies have reported on the long-term effects of ACEI, ARB, -blockers, and spironolactone. 22 Currently, we are conducting a randomized study based on the hypotheses that hANP is effective in the postoperative acute phase, and that ARB and aldosterone blockade are effective during long-term follow up. In the future, we will report the results of this study.
Recently, the efficacy of administration of hANP during and after PCI for AMI and ACS has been reported, however, no investigation had been conducted until the present study, which investigated the usefulness of hANP administration in cases undergoing CABG. The present study demonstrated that continuous low-dose administration of hANP initiated during CABG attenuates ischemia-reperfusion injury, protects the myocardium, suppresses LV remodeling, has an anti-arrhythmic effect, and protects the kidneys. Thus, we propose that hANP is a useful drug for intraoperative and postoperative management of patients with CPB undergoing cardiac surgery.
Conclusion
In the present study, we investigated the efficacy of continuous low-dose administration of hANP from the start of CPB in ACS cases undergoing emergent CABG. The results of the study demonstrated that hANP is not only effective for overcoming the major problems associated with CPB, but also attenuates ischemia-reperfusion injury, protects the myocardium, suppresses LV remodeling, has an anti-arrhythmic effect, and protects the kidneys, thereby suggesting that hANP administration as described is also effective in cases of ACS undergoing emergent CABG.
